Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Levetiracetam

Preparation Calculator

USE IF: Seizure control (focal / GTCS contexts per labeling); acute loading pathways when protocol allows β€” with renal dosing, behavioral monitoring, and IV/PO mg plan.

AVOID IF: Continuing without renal adjustment when GFR falls; ignoring new agitation/mood symptoms; abrupt stop without seizure risk plan; hypersensitivity.

Levetiracetam

Antiepileptic (SV2A modulator)

AdultPediatricNeurologyERWardICUHigh-yield

Indication

Focal seizures β€’ GTCS β€’ SE adjunct (pathway) β€’ Selected prophylaxis (protocol-only)

At a glance

INDICATIONS (CORE USE)

- Focal seizures - Generalized tonic-clonic seizures - Adjunct in status epilepticus pathways (institution-specific)

ADULT DOSE (STANDARD)

Loading (acute IV): ~1–3 g total β€” protocol-based only Maintenance: 500–1500 mg BID (individualize) IV and PO IR: 1:1 mg conversion for total daily dose Adjust for renal function (mandatory)

MAX DOSE

Individualized β€” titrate to seizure control, renal function, and behavioral tolerance

Route

PO / IV (interchangeable mg for IR)

PEDIATRIC DOSE

Weight-based / protocol-driven

Do not miss

Must-not-miss safety points

Major warning

- Behavioral / neuropsychiatric effects (agitation, irritability, mood changes) β€” not behavior-neutral - Renal impairment β†’ dose adjustment required - Rapid IV loading common in acute care β€” protocol-based only - Abrupt discontinuation may increase seizure risk - Additive sedation with CNS depressants

Indications

Primary

  • Focal seizures
  • Generalized tonic-clonic seizures

Secondary

  • Status epilepticus (adjunct; common off-label / pathway practice)
  • Seizure prophylaxis (selected contexts only β€” protocol-driven)

Dosing

STANDARD (ADULT PO)

Loading (acute IV): ~1–3 g β€” protocol-based only Maintenance (adult): 500–1500 mg BID (titrate to effect)

ADULT DOSE

IV and PO immediate-release: **1:1 mg/day equivalence** when switching routes. **Renal impairment:** reduce dose and/or prolong interval per CrCl/eGFR tier table (label / institutional). **Dialysis (ESRD):** supplemental dosing around dialysis per protocol. Acute loads: infusion duration / repeat bolus rules per local guideline.

PEDIATRIC DOSE

Weight-based; acute loads protocol-defined

MAX DOSE

No universal fixed max β€” individualized to efficacy, renal function, and tolerability

Practical Note

- Do not substitute XR/ER for IR without recalculating total daily mg and formulation rules - After AKI or major renal shift, reassess dose before continuing home regimen - Taper when discontinuing chronic therapy when feasible

Warnings

Clinical warnings

  • Behavioral changes: agitation, irritability, hostility, anxiety, depression, emotional lability
  • Somnolence, fatigue, dizziness, ataxia
  • Rare psychosis / paranoid symptoms β€” higher vigilance with psychiatric history and ICU course
  • Generally minimal enzyme-mediated drug interactions vs many AEDs β€” still subject to additive CNS depression

Contraindications

  • Known hypersensitivity to levetiracetam or product components

Drug interactions

  • Minimal clinically significant CYP-based interactions vs many antiepileptics
  • Practical stack risk: additive sedation with benzodiazepines, opioids, propofol, alcohol

Special populations

Pediatrics

Weight-based / protocol-driven

Pregnancy

Pregnancy: risk–benefit with neurology/obstetrics; seizure control drives decisions.

Lactation

excreted in milk; monitor infant for sedation or irritability per local guidance.

Renal impairment

Dose reduction required; dominant renal clearance β€” reassess after renal insult or dialysis changes.

Hepatic impairment

Not primarily hepatic; integrate with encephalopathy / sedation confounders in severe liver disease.

Elderly

Increased sensitivity to sedation and confusion; often lower effective clearance β€” verify renal dosing tier and fall risk.

Administration

- PO or IV - IV loading common in acute settings β€” rate and monitoring per protocol - Easy switch IV ↔ PO for IR using same total mg/day - Oral solution / tablet per patient ability; verify formulation when converting

Monitoring

  • Monitor: - Seizure control / ICU seizure events - Mental status and behavioral symptoms - Renal function (eGFR / CrCl trend)
  • Recheck: - After load, titration, dialysis, or formulation switch - Periodically on chronic therapy
  • If ongoing seizures or unclear benefit at 48–72h on optimized dose β†’ reassess diagnosis, levels (if used), and pathway; do not continue blindly without neurology escalation
  • Hold / reassess: - Severe behavioral disturbance - Profound sedation out of proportion - Renal deterioration without dose adjustment

Overdose / toxicity

Clinical Picture

Sedation; respiratory depression greater with co-ingestants; behavioral changes

Immediate Actions

Supportive care; airway and respiratory support as needed; toxicology consult if massive ingestion

Antidote

None

Decontamination

Charcoal may be considered for recent oral ingestion if airway protected β€” context-specific

Escalation

ICU monitoring for severe CNS depression; dialysis removes drug β€” consider in relevant contexts per toxicology

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Among the easier AEDs for interaction checking β€” behavioral toxicity is the common limiter
  • IV ↔ PO IR: same mg/day

Clinical

  • Renal adjustment is not optional
  • Agitation on levetiracetam is a real stop/taper/dose decision

Safety

  • Redose after dialysis per protocol
  • Avoid abrupt discontinuation when seizures active

Pharmacy Tool

Preparation Calculator

Levetiracetam 100 mg/mL oral solution

solution Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Renal clearance dominant - Linear kinetics in usual dose ranges when renal function stable - Half-life prolonged in renal impairment

Mechanism of action

- SV2A (synaptic vesicle protein) modulation β†’ reduced pathologic neuronal hyperexcitability

Common brand names

Saudi Arabia

Keppra, Levetiracetam

Global

Elepsia XR (example), (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Local status epilepticus / neurology ICU pathways
  • FDA / SFDA product labeling (Keppra and generics)
  • Institutional renal dosing tables for AEDs